DexCom, Inc. · NASDAQ:DXCM
DexCom — Technical Presentation (2013)
38 slides from DexCom's technical presentation, 2013
Slide 1: 2013 CGM Category Update — Dexcom G4 PLATINUM and Clinical Literature
2013 CGM Category Update — Dexcom G4 PLATINUM and Clinical Literature
Slide 2: LBL-012178 Rev 01 2
LBL-012178 Rev 01 2
Slide 3: Damiano et al. Head To Head Comparison with Navigator, G4 PLATINUM and Enlite
Damiano et al. Head To Head Comparison with Navigator, G4 PLATINUM and Enlite © 24 closed-loop BG control experiments 48 hours in length including six meals and ~ 30 minutes of exercise © Each subject wore three CGM devices on abdomen: ~ Abbott Freestyle Navigator ~ Dexcom G4 Platinum — Medtronic En
Slide 4: Head-to-Head CGM Comparison
Head-to-Head CGM Comparison Abbott Dexcom Minimed sara sate G4 Platinum Enlite (Veo) Navigator Clarke Grid Se Repression Analysis G+ Platinum Clarke Grid de Repression Analysis Enlize Clare Grid & Repression Analysis ebm inege hcbod \ GAZH, 29588 05%C] PS&D) | — 5, Intercepes' near 27426 mpg MARDS:
Slide 5: MARDs in Plasma Glucose Ranges
MARDs in Plasma Glucose Ranges @ Navigator 7 7 §G4 BEnlite 30 S Ss a I =z 120 — 180 180 — 250 > 250 Plasma Glucose (mg/dl) Damiano et al. 73" ADAScientific Sessions. June 23, 2013. 171-OR. 70 — 120 LBL-012178 Rev 01 5
Slide 6: Consistent & Accurate Performance with Dexcom G4 PLATINUM
Consistent & Accurate Performance with Dexcom G4 PLATINUM QO A G4 Enlite S & 50 & 50 | : ga ge 5 5 a 5 | & oll t iil: Hi! & 2 Q Q Hit Hil Me Ot 0% % 10) iHili| Ahi | Hh ii, LOR | < < oe AL un lalla a, < 0 me were a > > 300 > 7 1 a Plasma tae (mg/dl) = Plasma Glucose (mg/dl) MARDs with Standard Devia
Slide 7: Rate Accuracy Among CGM Systems
Rate Accuracy Among CGM Systems During Glucose Rate of Change BNavigator @c4 @eEnlite ~ wuudud 0-025 025-05 05-075 075-1 1-15 1s=2 2995 " gs=3:”° 324 " jag (N=948) (N=355) (N=680) (N=398) (N=652) (N=312) (N=192) (N=112) (N=106) (N=84) |Rate of Change in CGMG — Rate of Change in PG| (mg/dl/min) o we
Slide 8: Conclusions
Conclusions © Dexcom G4 PLATINUM accuracy is markedly improved vs. Seven Plus © Dexcom G4 PLATINUM accuracy is better than the Navigator and markedly better than Guardian, and Enlite (Veo) © Calibration remains an important, and preventable source of error © Highly accurate meter are necessary to re
Slide 9: Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes
62>) The NEW ENGLAND ‘ee’ JOURNAL off MEDICINE Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group LBL-012178 Rev 01 9
Slide 10: JDRF RT-CGM Randomized Controlled Trial
JDRF RT-CGM Randomized Controlled Trial Subjects ® n=322 © 3cohorts by age: 8-14, 14-24, > 25 yrs old ® Atc 7.0% - 10.0% © CSII(79.5%) or MDI (20.5%) © SMBG mean 6.4 tests per day Treatment Groups © Real-time CGM + SMBG group ~ Abbott, DexCom or Medtronic RT Sensors © SMBG control group New Engl J M
Slide 11: Cohort Starting with A1c 7.0-10.0%
Cohort Starting with A1c 7.0-10.0% Changes in A1tc in >25 yr olds Control YA.) -+RT-CGM 7.0 Difference: -0.53% p-value <0.001 6.5 Baseline 13 weeks 26 weeks *Error bars stand for 95% CI. New Engl J Med 2008: 359: 1464-1476 yee me
Slide 12: Change in A1c from Baseline to Weeks in ≥7.0% HbA1c Cohort
Change in A1c from Baseline to 26 Weeks in 27.0% HbA1c Cohort CGM _ Control CGM _ Control CGM _ Control 0.02 | -0.22 -0.37 = = oOo 1 Ee -0.18 -0.21 55 of won — Change in HbA1c ooo ao on & -0.50 225yrolds 15-24 yr olds 8-14 yr olds P<0.001 P=0.52 P=0.29 New Engl J Med 2008: 359: 1464-1476 LBL-012178
Slide 13: Change in A1C by Sensor Use
Change in A1C by Sensor Use Age 225 Age 15-24 Age 8-14 0.17 F a .-: n=43 n=10 299 n=17 n=7 y=21 n=28 n=1 ia Si -0.15 Oo x 0.25 £ 3 -0.35 = 0.44 o 0.5 P=0.002 P=0.02 -0.65 07 ()) <4.0 days/week sensor use . )) 4.0-<6.0 days/week sensor use P<0.001 -0.8 26.0 days/week sensor use Age (Years) Diabetes C
Slide 14: A1c Change in ≥7.0% A1c Cohort with CGM Use
A1ic Change in 27.0% A1c Cohort with CGM Use 2 6 days/week at Month 12 Age 15-24 Age 8-14 N=6 N=15 = S02 5 — ) = -0.4 +— < 06 0.5 -0.5 0.5 = 0-26wks om = 0-52wks o D -0.8 OT ec 0.8 © = + Ss) -1.0 Diabetes Care 2009; 32:2047-2049 HBR Ta
Slide 15: Cohort Starting with A1c < 7.0%
Cohort Starting with A1c < 7.0% Changes in A1c From Baseline to 26 Weeks 6.0 Baseline 13 weeks 26 weeks *Error bars show the 95% confidence interval (Cl). Diabetes Care 2009: 32:1378-1383 LBL-012178 Rev01 15
Slide 16: Hypoglycemic Sensor Glucose Outcomes in <7.0% HbA1c Cohort
Hypoglycemic Sensor Glucose Outcomes in <7.0% HbA1c Cohort Frequency of CGM Glucose Levels § 70,60 ands 50 mg/dL 120 P= 0.05 96 99 Each comparison Baseline vs 13 and 26 wks 100 91 pes 80 + 68 49 P=0.01 ao 42 j 23 P=0.05 20 7s 9 10 0 | En Fa CGM Control CGM Control CGM Control $70 mg/dL $60 mg/dL $50
Slide 17: DCCT: Absolute Risk of Severe Hypoglycemia by Mean A1c
DCCT: Absolute Risk of Severe Hypoglycemia by Mean A1c faa 8 l 8 1 s Sx 3 & ae 80 - DCCT: 1986 to 1993 Ss ° 8 60 - o> ce a: —_ oe = ee i . 0 1 q ! 1 q q q 1 q ! ! 5.0 55 6.0 65 7.0 7.5 8.0 85 9.0 9.5 10.0105 Glycosylated Hemoglobin (%) DCCT. N Engl J Med 1993;329:977-86 LBL-012178 Rev01 17
Slide 18: Two Eras of Diabetes Management
Two Eras of Diabetes Management 100 - 40- JDRF CGM Study Control Group * saaeaadl ae Rate of severe Hypoglycemia (per 100 patient-years) 1 q ! 1 q q q 1 q ! ! 5.0 55 6.0 65 7.0 7.5 8.0 85 9.0 9.5 10.0105 Glycosylated Hemoglobin (%) DCCT. N Engl J Med 1993;329:977-86 JDRF. N Engl J Med 2008;359:1464-
Slide 19: Impact of Continuous Glucose Monitoring on Rate of Severe Hypoglycemia Compared to DCCT
Impact of Continuous Glucose Monitoring on Rate of Severe Hypoglycemia Compared to DCCT 120 - \ o \ Ee. 104 \ 38 ; eh 80, S§ =s 5 = Lo $2 33] es g 2- 0 i] Age 2 25 years with A1C < 7.0% BB Age 8-14 years with A1C <7.0% Age 15-24 years with A1C < 7.0% @ Age 2 25 years with A1C 2 7.0% @ Age 15-24 year
Slide 20: Results of the ASPIRE Low Glucose Suspend Study published in NEJM in June 2013
Results of the ASPIRE Low Glucose Suspend Study published in NEJM in June 2013 The NEW ENGLAND JOURNAL of MEDICINE | ORIGINAL ARTICLE } Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia Richard M. Bergenstal, M.D., David C. Klonoff, M.D., Satish K. Garg, M.D., Bruce W. Bode, M.
Slide 21: Positive Result, But Some Significant Questions
Positive Result, But Some Significant Questions DIABETES TECHNOLOGY & THERAPEUTICS Volume 15, Number 7, 2013 1 © Mary Ann Liebert, Inc. DOk 10.1089/dia.2013.0174 Diabetes Technology & Therapeutics EDITORIAL Reducing Hypoglycemia in Type 1 Diabetes: An Incremental Step Forward In B. Hirsch, MD ONTINU
Slide 22: Hirsch Commentary in DTT (2013) was Positive, but Raised a Number of Questions
Hirsch Commentary in DTT (2013) was Positive, but Raised a Number of Questions © “itis exciting to see that threshold suspend with SAP is safe, does not cause rebound hypoglycemia and is the next step for the technological holy grail of an automated closed loop pancreas” © “But before we celebrate t
Slide 23: Suspension of Basal Insulin Infusion is Not a Recommended Method for Reversing Hypoglycemia
Suspension of Basal Insulin Infusion is Nota Recommended Method for Reversing Hypoglycemia © ADA Standards of Care in Diabetes - 2014 (Diabetes Care 37:S14-S80 2014) ® “Glucose (15-20 g) is the preferred treatment for the conscious individual with hypoglycemia, although any form of carbohydrate that
Slide 24: Implications of the 11.9 min Median Cessation of Basal Insulin Infusion
Implications of the 11.9 min Median Cessation of Basal Insulin Infusion © 50% of the suspensions < 11.9 minutes! ® What might have actually happened? ~ Patients performed SMBG and disregarded action of Veo LGS threshold suspend? ~ Patients treated hypoglycemia with glucose? ~ Basal insulin suspensio
Slide 25: Journal of Diabetes Science and Technology
Journal of Diabetes Science and Technology Volume 7, Issue 4, July 2013 SYMPOSIUM LBL-012178 Rev 01 25
Slide 26: Performance of G4 Platinum
Performance of G4 Platinum Overall MARD = 10.9+1.5% Bbdbag Pleus et al. J Diab Sci Tech 2013;7:833-841 LBL-012178 Rev 01 26 MARD (%) oye pe Seer rererse.
Slide 27: Performance of G4 PLATINUM: PARD
PARD (%) Performance of G4 PLATINUM Overall PARD = 7.3+1.9% Precision Absolute Relative Difference (differences between paired CGM readings) fates T 4 5 6 7 Day Pleus et al. J Diab Sci Tech 2013;7:833-841 LBL-012178 Rev 01 27
Slide 28: Performance of Commercial CGMs
10} (0) (0) {0} Performance of Commercial CGMs MARD PARD Navigator 12.4+3.6 10.1+4.1 Enlite 16.4+6.9 16.7+3.8 Seven-Plus 16.74+3.8 15.4+4.2 G4 Platinum 10.9715 7.3419 Institut fir Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universitat Ulm, Ulm Germany Freckmann et al. J
Slide 29: Dexcom G4 PLATINUM Pivotal Trial Data — DTT Published Study
Dexcom G4 PLATINUM Pivotal Trial Data — DTT Published Study Christiansen et al. First publication on the accuracy and performance of the Dexcom G4® PLATINUM CGM system and the data is based on our pivotal trial data. The purpose of this study is to compare the accuracy and reliability of the new Dex
Slide 30: Accuracy and Reliability Data for the Dexcom G4 PLATINUM
Accuracy and Reliability Data for the Dexcom G4 PLATINUM ——eEeOO | OVERALL ACCURACY i scomga pee or cL) | 400mg/dL pears mg/dL i é —e G4 Sect oon — pole LBL-012178 Rev 01 30
Slide 31: Key Talking Points with Dexcom G4 PLATINUM Published Study
1] © © © © Key Talking Points with Dexcom G4 PLATINUM Published Study The data published in this study is what was submitted to the FDA. Performance data is what the Dexcom G4 PLATINUM performance really is and what patients would see in daily life based on home use. Dexcom G4 PLATINUM has delivered
Slide 32: Focus on Hypoglycemia Accuracy with the Dexcom G4 PLATINUM
Focus on Hypoglycemia Accuracy with the Dexcom G4 PLATINUM TABLE 1 padilga clita teteetot Ac abtaety eh sp weir eae | CGN-YSI Overall Overall Overall Clarke MAD <70 %20/20 Clarke Error Grid matched data MARD %20/20_— Error Grid “A” mg/dL 40-80 mg/dL “A” 40-80 mg/dL Medtronic Guardian RT Abbott Navig
Slide 33: CGM Brand DOES Make a Difference with Continued Use
CGM Brand DOES Make a Difference with Continued Use Exactly one year after starting your CGM system, how often were you wearing it? [Bl Mesticonic Minitink (n= 43) Almost 3 Weeks/ 2 Weeks/ 1 week or Daily Month Month Less/Month Medtronic Miniliak (od3) 8 (19%) 6 (14%) 1 (2%) 28 (65%) eer SEVEN PLUS
Slide 34: More CGM Users Would Purchase the Dexcom CGM Than Any Other Brand
More CGM Users Would Purchase the Dexcom CGM Than Any Other Brand Would you purchase the same system again if given the chance? Yes No Medtronic MiniLink (n=43) 19 (44%) 24 (56%) Would you try another syst if given the chance? Dexcom SEVEN PLUS (n=38) 35 (92%) 3 (7%) em No 100% 50% 0% Yes Chamberlai
Slide 35: Dexcom G4 PLATINUM Safety Statement
Dexcom G4 PLATINUM Safety Statement INDICATIONS FOR USE The Dexcom G4 PLATINUM Continuous Glucose Monitoring System is a glucose-monitoring device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The system is intended for single patient use and requi
Slide 36: Dexcom G4 PLATINUM Safety Statement: Warnings
Dexcom G4 PLATINUM Safety Statement WARNINGS * Thoroughly review the training materials included with your CGM system before using the Dexcom G4 PLATINUM CGM System. Incorrect use might lead to you misunderstanding the information provided by your system, or might affect system performance, and you
Slide 37: Dexcom G4 PLATINUM Safety Statement: Precautions
Dexcom G4 PLATINUM Safety Statement PRECAUTIONS * Before opening the sensor package, wash your hands with soap and water, and let them dry. You may contaminate the insertion site and suffer an infection if you have dirty hands while inserting the sensor. + Before inserting the sensor, clean the skin
Slide 38: Dexcom G4 PLATINUM Safety Statement
Dexcom G4 PLATINUM Safety Statement * Keep the USB port cover on the receiver closed whenever the USB cable is not attached. If water gets into the USB port, the receiver could become damaged and stop displaying readings or providing alerts, and you might miss a low or high blood glucose value. + Do